Quantcast

Parkinson's biotech Prevail Therapeutics sets terms for $125 million IPO


Shutterstock photo

Prevail Therapeutics, an early stage biotech developing gene therapies for neurodegenerative diseases, announced terms for its IPO on Monday.

The New York, NY-based company plans to raise $125 million by offering 7.4 million shares at a price range of $16 to $18. At the midpoint of the proposed range, Prevail Therapeutics would command a fully diluted market value of $672 million. 

Prevail Therapeutics was founded in 2017 and plans to list on the Nasdaq under the symbol PRVL. Morgan Stanley, BofA Merrill Lynch and Cowen are the joint bookrunners on the deal. It is expected to price during the week of June 17, 2019.

The article Parkinson's biotech Prevail Therapeutics sets terms for $125 million IPO originally appeared on IPO investment manager Renaissance Capital's web site renaissancecapital.com.

Investment Disclosure: The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital's Renaissance IPO ETF (symbol: IPO) , Renaissance International ETF (symbol: IPOS) , or separately managed institutional accounts may have investments in securities of companies mentioned.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.





This article appears in: News Headlines , IPOs



More from Renaissance Capital

Subscribe







Renaissance Capital
Contributor:

Renaissance Capital

IPOs












Research Brokers before you trade

Want to trade FX?